Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call

April 2, 2020 Off By BusinessWire

Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2020 fiscal year, the period ended February 29, 2020, on Thursday, April 9, 2020.

The Company will host a conference call on April 9, 2020, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering here. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (914) 614-3221, and enter access code 938-770-331. A replay will be available at the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche

661-723-7723

[email protected]

Hayden IR
Mr. Cameron Donahue

651-653-1854

[email protected]